Publications

1502 Tubular-Infiltrative Variant of Acinar Cell Carcinoma: Clinicopathologic Analysis of 11 Cases of A Distinct Entity Invariably Misdiagnosed as Ductal Adenocarcinoma

D Bahceci, N Tezcan, B Memis, W Park, E O'Reilly, D Klimstra, O Basturk, ...

1O ATOMIC (A021502/AIO-KRK-0317): Does duration of adjuvant chemotherapy (chemo) or immunotherapy matter?

A Reinacher-Schick, FS Ou, D Hsu, CH Lieu, D Cohen, K Matin, ...

342O Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+ metastatic pancreatic adenocarcinoma (mPAC): phase II GLEAM …

W Park, L Shen, MP Ducreux, S Mitsunaga, G Roth, B Shen, ...

425P Arterial thromboembolism in pancreatic ductal adenocarcinoma: A marker of advanced disease and poor survival

A Syal, K Yu, W Park, C O'Connor, M Capanu, J Chou, C Schwartz, ...

430P CLDN18. 2 and KRAS signaling shape tumor states and immune microenvironment in pancreatic cancer (PC)

V Nasca, M Hilmi, N Tezcan, M Perry, M May, J Song, F Balogun, ...

472TiP RASolute 304: A phase III multicenter, open-label, randomized study of adjuvant daraxonrasib versus observation following completion of neoadjuvant and/or adjuvant …

MP Ducreux, D Chang, M Ikeda, A Lowy, TM Mercade, ZA Wainberg, ...

A phase 2/3 randomized study of BMS-986504 with nab-paclitaxel (nab-P) and gemcitabine (GEM) in first-line (1L) metastatic pancreatic ductal adenocarcinoma (PDAC) with …

S Pant, MP Ducreux, M Ikeda, X Yu, EM O'reilly, G Trandafirescu, ...

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer

Alagesan B, Varghese AM, Ang C, Gutierrez M, Kamar M, Passhak M, Geva R, Yarom N, et al.

Abstract A042: ctDNA KRAS detection in pancreatic ductal adenocarcinoma: Platform concordance, sensitivity and clinical associations in a contemporary cohort

J Guo, M May, MF Berger, E Cismas, M Hilmi, A Singhal, F Balogun, ...

Abstract A050: Mutant allele copy number gains define distinct molecular subtypes of oncogene-driven cancers and are associated with response to allele-specific KRASG12C …

MA Perry, AL Richards, A Price, SE Tischfield, H Walch, H Xie, ...

Abstract A124: Prevalence, Treatment Patterns, and Outcomes of Organ Dysfunction at Diagnosis in Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Institution Analysis of 3 …

E Cismas, RB Forman, J Zheng, Q Shi, W Park, M Pishvaian, ...

Abstract A140: Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC

AN Habowski, FM Kouassi, J Rouse, J Hinds, H Patel, C Tsang, L Kelly, ...

Abstract IA008: Pancreas cancer: Genomics, RAS therapeutics and clinical landscape

EM O'reilly

Abstract LB337: Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC)

EM O'Reilly, B Wolpin, S Pant, JR Hecht, J Valerin, DW Kim, N Azad, ...

Abstract LB423: Invigorating pre-existing tumor-infiltrating expandable (TIE) T cell clonotypes in exceptional responders with dual PARP-PD-1 blockade in homologous …

M Hilmi, W Mckerrow, JD Schoenfeld, S Umeda, N Tezcan, C O'Connor, ...

Abstract SY36-02: Human cancer models: From patient-derived systems to clinical translation

AN Habowski, F Kouassi, H Patel, J Rouse, C Tsang, L Kelly, D Plenker, ...

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703)

K Ng, FS Ou, T Zemla, NA Jackson, A Kalyan, C Devoe, M Shusterman, ...

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848

Abrams RA, Winter KA, Goodman KA, Regine WF, Safran HP, Guha CS, Kachnic LA, Gillin MT, et al.

Adjuvant Chemotherapy Alone or Combined with Atezolizumab in Patients with Stage III Deficient DNA Mismatch Repair (dMMR) Colon Cancer-Results of the Randomized ATOMIC Trial …

D Arnold, S Hegenberg, J von Tresckow, A Stahler, E Goekkurt, ...

Alliance A022104/NRG-GI010, a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free …

CS Kitchens, Q Shi, A Dasari, J Garcia-Aguilar, HK Sanoff, TJ George, ...

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Lavoie Smith EM, Lee M, Scott MR, Liu H, Hillman S, Rieken T, Wills R, Diaz-Cobo J, et al.

Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wasting

Boscenco S, Castillon VJ, Wang J, Tse E, Freeman SS, Bakouny Z, Mohan S, Guo XA, et al.

ASO Visual Abstract: Outcomes of First-versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Nasar N, Armstrong M, Chou JF, Gonen M, Soares KC, Balachandran VP, Drebin JA, Kingham TP, et al.

Association of genomic and clinical factors with outcomes with front-line chemoimmunotherapy in patients with advanced biliary tract cancer.

OM Fitzpatrick, J Chou, J Xu, A Dhyani, DN Khalil, F Nagib, F Keane, ...

Associations of WCRF/AICR recommendations with survival and chemotherapy outcomes in colon cancer: CALGB/SWOG 80702 (Alliance)

E Cheng, C Ma, Q Shi, AF Shields, PT Campbell, AP Shergill, KA Guthrie, ...

Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study

Manji GA, Chung V, Oh DY, Lacy J, Lopez CD, Ponz-Sarvisé M, Macarulla T, Thomas R, et al.

Atezolizumab plus FOLFOX for stage III mismatch repair–deficient colon cancer

FA Sinicrope, FS Ou, D Arnold, WR Peters, RJ Behrens, CH Lieu, K Matin, ...

Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials

Lewis KA, Colgrove BA, Nelson GD, Shi Q, Edwards GC, Katz MHG, Chang GJ, Paskett ED, et al.

BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

JJ Harding, R Hofheinz, E Élez, Y Kuboki, DW Rasco, M Cecchini, L Shen, ...

Biomarker and pharmacokinetics (PK) analyses of zolbetuximab from the phase 2 GLEAM study in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+ metastatic pancreatic …

W Park, L Shen, MP Ducreux, S Mitsunaga, G Roth, B Shen, ...

Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)

JR Strosberg, T Zemla, S Geyer, S Pulsipher, FS Ou, S Behr, N Raj, ...

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

C Bandlamudi, D Muldoon, I de Bruijn, M Zhang, MV Gormally, ...

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors

Melero I, Tabernero J, Steeghs N, Robbrecht DGJ, Peters S, Rizvi NA, O'Reilly EM, Calvo E, et al.

Characterization of antibody-drug conjugate target antigen expression in patients with biliary tract cancer.

A Dhyani, N Tezcan, J Chou, Z Tarcan, R Thummalapalli, F Nagib, ...

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic …

EM O’Reilly, CR Cabanski, JP Lyman, ZA Wainberg, GA Fisher, RA Wolff, ...

Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer

Hong J, Kohutek ZA, Zhang H, Lecomte N, Karnoub ER, Kappagantula R, Wood LD, O'Reilly EM, et al.

CONVERSION HEPATECTOMY FOLLOWING HEPATIC ARTERY INFUSION PUMP THERAPY FOR UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA

M Mederos, R Harvey, M Gonen, A Nigam, L Saadat, K Soares, A Wei, ...

Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC)

EM O’Reilly, B Wolpin, S Pant, JR Hecht, J Valerin, DW Kim, N Azad, ...

Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer

EM O’Reilly, ZA Wainberg, AE Hendifar, MJ Borad, F Pietrantonio, S Pant, ...

Daraxonrasib, a RAS (ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase …

BM Wolpin, ZA Wainberg, A Hendifar, MJ Borad, F Pietrantonio, S Pant, ...

Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer

Forjaz A, Mojdeganlou H, Valentin A, Wetzel M, Lvovs D, Deshpande A, Shin SM, Piya S, et al.

Dual pancreatic carcinomas: clonally related or independent primaries?

Schoenfeld JD, Ravichandran V, Tarcan Z, Sahin-Ozkan H, Richards AL, Bilani N, Chou JF, O'Connor CA, et al.

Efficacy and safety of cabozantinib (CABO) in advanced neuroendocrine tumors (NET) according to hormone functional status: Subgroup analysis of phase 3 CABINET trial (Alliance …

N Trikalinos, SM Geyer, T Zemla, JR Strosberg, EM Wolin, ...

Endoscopic Ultrasound-Guided Biomarker Evaluation of Pancreatic Cancer After Exposure to Therapy

SE Lee, D Kim, V Rolston, E Vakiani, C Sigel, EM O'reilly, K Yu, ...

ESMO podcast on upper GI cancers: highlights in hepatocellular carcinoma and pancreatic cancer from ESMO 2025

J Dekervel, A Vogel, E O’Reilly

Establishing the minimum future liver remnant volume for safe hepatectomy

JA Steinharter, J Chou, CH Ilagan, M Gönen, LV Saadat, K Soares, ...

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma

Harvey RN, Gelfer R, Drill E, Balachandran V, D'Angelica M, Drebin J, Kingham TP, Saadat L, et al.

Evaluating the prognostic impact of IDH mutations in intrahepatic cholangiocarcinoma.

R Gelfer, R Harvey, EN Drill, VP Balachandran, MI D'Angelica, JA Drebin, ...

Evaluation of progression-free survival as a surrogate endpoint for overall survival in localized pancreatic cancer: Trans-Atlantic Pancreatic Surgery Consortium Study

J Okui, MG Besselink, AC Wei, EM O’Reilly, BG Koerkamp, S Ceuppens, ...

Excellent 2-and 3-Year OS after Ablative MRgRT for Localized Pancreatic Cancer without Surgery

M Reyngold, V Kirichenko, E O'Reilly, M Mcmillan, AJ Wu, PB Romesser, ...